Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme that protects red blood cells from oxidative damage. A "deficiency" in G6PD—a genetic variant that reduces the enzyme's activity—should be selected against. It makes cells vulnerable to hemolysis (destruction) when exposed to oxidative stressors. Yet G6PD deficiency is the most common enzymatic disorder in humans, affecting 400+ million people worldwide, with highest frequency in populations from malaria-endemic regions: Sub-Saharan Africa, Mediterranean, Middle East, South Asia.
The paradox resolves when you understand what G6PD deficiency actually does: it provides partial protection against malaria while creating vulnerability to specific drugs and foods.
The mechanism is this: malaria parasites (Plasmodium species) infect red blood cells and depend on the cell's metabolism to survive. A red blood cell with G6PD deficiency has reduced antioxidant capacity. When the cell is infected, this creates an inhospitable environment for the parasite—oxidative stress that the parasite cannot tolerate. The infected cell is slightly more likely to be destroyed by the immune system. The parasite burden drops.
The cost: the individual is vulnerable to hemolytic crisis if exposed to:
The trade-off was worth it. In a population where malaria killed 30% of children, the probability of encountering fava beans was low, antimalarial drugs did not exist, and the genetic variant that reduced malaria deaths while creating vulnerability to occasional hemolysis was selected for.
G6PD deficiency is not a deficiency. It is an adaptation to a specific ecological niche: high malaria load, low frequency of triggering stressors.
When antimalarial drug programs introduced primaquine in the 1950s-1970s to suppress malaria transmission, they triggered hemolytic crisis in G6PD-deficient individuals. The drug, designed to kill the parasite, instead destroyed red blood cells in genetically susceptible populations.
This created a medical paradox: the drug that was supposed to prevent malaria was causing acute illness in the very populations most at risk from malaria. G6PD-deficient individuals who took antimalarial drugs experienced:
The response: divide populations by G6PD status. Screen for the variant; give primaquine only to those without it. This slowed malaria suppression campaigns because it required genetic testing before treatment. But it prevented drug-induced hemolytic crisis.
The deeper point: the genetic variant that conferred an advantage in the ancestral environment became a liability in the modern medical environment. The drug and the gene were in conflict. You could not medicate G6PD-deficient populations without triggering harm, yet those populations had the highest malaria prevalence.
G6PD deficiency frequency maps almost perfectly onto historical malaria endemicity:
High prevalence (>20% of population):
Low prevalence (<2%):
The correlation is not perfect—some high-malaria regions have lower G6PD frequencies, likely because other antimalarial adaptations (sickle cell, thalassemia) competed for the same selective pressure. But the overall pattern is unmistakable: G6PD variant geography follows malaria geography.
This is population-level evidence of recent (last 5,000-10,000 years) selection pressure. The variant persists because it provides enough antimalarial benefit to outweigh the cost.
G6PD deficiency reveals a conflict built into modern medicine: drugs designed for populations without the variant are toxic to populations with the variant. This is not medical error—it is evolutionary biology asserting itself in the medical encounter.
The solution is not to eliminate G6PD variants (they confer advantage against malaria). The solution is to screen populations, understand the genetic architecture of disease resistance, and design drug protocols that account for the variant's presence.
But this is resource-intensive. It requires:
Many malaria-endemic regions lack these resources. The simplest approach—give everyone primaquine—causes harm to G6PD-deficient individuals. The careful approach—screen first, then treat—requires infrastructure many populations do not have.
G6PD deficiency is thus a window into a broader problem: modern medicine was designed by and for populations without certain genetic variants. When that medicine is deployed in genetically different populations, it sometimes harms the very people it was meant to help.
History: Franklin Expedition & Lead Poisoning — Both G6PD and lead poisoning reveal how environmental exposure (malaria parasites, lead solder) selects for genetic variants. In Franklin's case, the crew had no genetic adaptation to lead poisoning because lead solder is a recent technology—their bodies had no evolutionary preparation. In G6PD populations, the variant is precisely the evolutionary preparation for malaria. The contrast reveals how adaptation lag operates: populations adapted to ancient hazards (malaria) are vulnerable to modern hazards (antimalarial drugs), while populations naive to ancient hazards are catastrophically unprepared when exposed (as Franklin's crew was to lead).
Anthropology: Local Adaptation & Global Medicine — G6PD demonstrates that "genetic deficiency" is context-dependent. The same allele is protective in malaria zones and harmful in zones with antimalarial drugs. Global health initiatives that apply one-size-fits-all medicine to genetically diverse populations will inevitably cause harm to some groups. The example of primaquine and G6PD-deficient populations shows this not as a rare edge case but as a systematic problem in tropical medicine.
The Sharpest Implication: A genetic variant that saved millions of lives under one set of conditions (high malaria, no drugs) became a liability under different conditions (drug-based malaria suppression). This illustrates a fundamental principle: adaptation is always specific to a particular environment. When the environment changes (especially when human technology introduces novel stressors), yesterday's adaptation becomes tomorrow's vulnerability. Modern medicine, by introducing antimalarial drugs, unwittingly created selection pressure against the variants that had been protective. The population with G6PD deficiency was not "deficient"—it was optimized for its historical ecology. The drug was the anomaly.
Generative Questions: